NASDAQ: SRZN - Surrozen, Inc.

Yield per half year: +41.17%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Surrozen, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Surrozen, Inc.

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. The company is developing antibody-based therapeutics with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.

more details
Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcoholic hepatitis and asialoglycoprotein receptor 1; and SZN-1326, a bi-specific antibody, which is in Phase 1b clinical trial for the treatment of moderate to severe inflammatory bowel disease, Frizzled, and LRP receptors. The company also develops SZN-413, a Fzd4 targeted bi-specific antibody, which is in preclinical stage for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. was founded in 2015 and is based in South San Francisco, California.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2021-01-11
ISIN US86889P1093
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.surrozen.com
Цена ао 11.89
Change price per day: 0% (11.59)
Change price per week: -1.02% (11.71)
Change price per month: +8.32% (10.7)
Change price per 3 month: +15.9% (10)
Change price per half year: +41.17% (8.21)
Change price per year: -13.02% (13.325)
Change price per 3 year: +219.28% (3.63)
Change price per 5 year: 0% (11.59)
Change price per 10 year: 0% (11.59)
Change price per year to date: -16.62% (13.9)
All parameters

Underestimation

Title Value Grade
P/S 1.35 9
P/BV 0.4458 10
P/E 0 0
EV/EBITDA 0.3831 10
Total: 6.13

Efficiency

Title Value Grade
ROA, % -93.41 0
ROE, % -113.46 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0822 10
Total: 9.8

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % 80.4 9
Yield EPS, % 416.44 10
Total: 7.2
More

Institutions Volume Share, %
Column Group LLC 627651 19.62
Euclidean Capital LLC 87696 2.74
Blackrock Inc. 58494 1.83
ArrowMark Colorado Holdings LLC 55123 1.72
Board Of Trustees Of The Leland Stanford Junior University 52131 1.63
Trustees Of Columbia University In The City Of New York 47930 1.5
Morgan Stanley 35211 1.1
Vanguard Group Inc 32511 1.02
Alyeska Investment Group, L.P. 20376 0.64
Geode Capital Management, LLC 11473 0.36

ETF Share, % Profitability for 1 year, % Dividends, %
iShares Micro-Cap ETF 0.00519 17.09 1.54048



Head Job title Payment Year of birth
Mr. Craig C. Parker M.B.A. CEO, President & Director 825.32k 1962 (63 years)
Mr. Charles Williams CFO, COO & Corporate Secretary 611.03k 1980 (45 years)
Dr. K. Christopher Garcia Ph.D. Co-Founder & Member of Scientific Advisory Board N/A
Dr. Roeland Nusse Ph.D. Co-Founder & Member of Scientific Advisory Board N/A 1950 (75 years)
Dr. Calvin Kuo M.D., Ph.D. Co-Founder & Member of Scientific Advisor N/A
Dr. Li Yang Ph.D. Executive Vice President of Research 535.46k 1969 (56 years)
Esther Jhun Controller N/A

Address: United States, South San Francisco. CA, 171 Oyster Point Boulevard - open in Google maps, open in Yandex maps
Website: https://www.surrozen.com